January 28, 2025 — Henan Lingrui Pharma Co., Ltd. ("Lingrui Pharma", 600285.SH) announced its plan to acquire a 90% shareholding in YinGu Pharmaceutical Co., Ltd. ("YinGu Pharma"), with a total acquisition price of RMB 704 million. Upon completion of the transaction, YinGu Pharma will become a controlled subsidiary of Lingrui Pharma.
YinGu Pharma is an innovative pharmaceutical company focused on R&D in chemical pharmaceuticals (including innovative and generic drugs), guided by clinical needs, and covering new drug development, raw material synthesis, formulation production, and pharmaceutical sales. Lingrui Pharma states that this acquisition will enhance its product portfolio in the orthopedics and respiratory therapeutic fields, supplementing its portfolio with topical and inhalable formulations featuring high technical barriers, such as nasal sprays and inhalants. The transaction is expected to generate synergies in sales, R&D, and other operational dimensions, aligning with Lingrui Pharma's strategic roadmap.
Han Kun Law Offices served as Lingrui Pharma's legal counsel in this transaction and provided comprehensive legal support throughout the transaction process, leading the design of the transaction structure, conducting legal due diligence, and drafting, revising, and negotiating transaction documents, culminating in the successful execution of definitive agreements. Han Kun is honored to have contributed to and witnessed this milestone transaction.